Studies 437 and 438 Secondary Endpoints

• Ranked assessment of liver histology

• Change in serum HBV DNA

  • Roche Amplicor? PCR, LLQ = 400 copies/mL

• Change in ALT

• HBeAg loss and seroconversion (Study 437)

• Resistance

Previous slide

Next slide

Back to first slide

View graphic version